Every material Form 8-K Avalyn Pharma Inc. has filed with the SEC since July 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Avalyn Pharma's board appointed Robert Meyer, M.D. as a Class II director effective September 15, 2026, with a term expiring at the 2028 annual meeting. The board determined he is independent under Nasdaq listing standards, and he brings prior FDA and drug-regulatory experience.
Robert Meyer, M.D. appointed Class II director effective September 15, 2026; term expires at the 2028 annual meeting
Annual director retainer of $40,000 under the Non-Employee Director Compensation Policy
Initial option grant for 31,182 shares of common stock, vesting in equal annual installments over three years
Avalyn Pharma reported a second-quarter 2026 net loss of $28.9 million, up from $20.2 million a year earlier, as research and development and general and administrative spending rose. The company is pre-revenue and reported no revenue in the filing, so the loss is its main financial measure, and the filing says its $413.5 million in cash is projected to fund operations into 2029.
Net loss was $28.9 million for the quarter ended June 30, 2026, versus $20.2 million for the same quarter of 2025.
R&D expenses rose to $24.7 million from $17.9 million, driven by the AP01 and AP02 clinical trials and the SAIL open-label extension study.
Cash, cash equivalents and marketable securities were $413.5 million at June 30, 2026, including about $316.6 million in net IPO proceeds from May 2026; the company projects runway into 2029.
Avalyn Pharma entered a First Amendment to its sublease with CRISPR Therapeutics, effective June 29, 2026, expanding the Boston premises from about 8,774 to about 13,708 rentable square feet. The amendment raises the company's future minimum lease payments by approximately $924,000 over the remaining lease term, a modest commitment that shareholders may want to note.
Effective date: June 29, 2026; the sublease covers 105 West First Street, Boston, Massachusetts
Premises expand from approximately 8,774 to approximately 13,708 rentable square feet
Future minimum lease payments increase by approximately $924,000 over the remaining lease term
All other terms of the original August 29, 2025 sublease remain in effect
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Avalyn Pharma Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →